# Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

> **NCT05624099** · PHASE2 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 75 (estimated)

## Conditions studied

- Esophageal Neoplasms
- Esophageal Diseases
- Digestive System Neoplasms

## Interventions

- **DRUG:** camrelizumab
- **DRUG:** Paclitaxel drugs
- **DRUG:** Platinum drug
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT05624099
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05624099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05624099, "Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05624099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*